Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea · Delayed Price · Currency is KRW

15,800

+950 (6.40%)

Aug 12, 2026, 3:30 PM KST

Onconic Therapeutics Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	67,205	53,392	14,838	21,056	95	60
Revenue Growth	196.21%	259.82%	-29.53%	22064.25%	58.33%	-
Gross Profit	67,191	53,381	14,835	21,054	-14,838	-8,342
Operating Income	15,627	12,619	-4,798	2,231	-14,838	-8,342
Net Income	20,328	15,784	-8,093	1,682	-14,432	-15,149
Earnings Per Share	441.04	347.92	-247.45	72.78	-624.23	-661.40
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	57,305	52,735	43,000	30,100	27,316	18,861
Total Debt	115.43	125.8	308.47	353.66	50.72	189.04
Net Cash (Debt)	57,190	52,609	42,691	29,747	27,265	18,672
Net Cash Growth	29.34%	23.23%	43.52%	9.10%	46.02%	-
Net Cash Per Share	1240.81	1159.65	1305.39	1286.70	1179.32	815.23

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	13,588	11,395	-7,841	4,140	-14,961	-8,859
Capital Expenditures	-342.9	-302.9	-141.28	-1,157	-2,575	-2.67
Free Cash Flow	13,245	11,092	-7,982	2,983	-17,536	-8,861
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	99.98%	99.98%	99.98%	99.99%	-	-
Operating Margin	23.25%	23.64%	-32.33%	10.60%	-15618.48%	-13903.24%
Pretax Margin	27.21%	25.70%	-67.00%	3.14%	-15191.48%	-25247.72%
Profit Margin	30.25%	29.56%	-54.54%	7.99%	-15191.48%	-25247.72%
FCF Margin	19.71%	20.77%	-53.79%	14.16%	-18458.96%	-14769.11%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 12, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	33.67	55.11	-	-	-	-
P/FCF Ratio	50.91	78.41	-	-	-	-
PS Ratio	10.03	16.29	11.90	-	-	-